Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

Growth Seen In First Full Quarter With Dual Migraine Indications

 
• By Mandy Jackson
  
Blue Arrows Rising up in wood blocks
Nurtec ODT revenue grew from $43.8m in Q1 to $93m in Q2 and now $136m in Q3 • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip